Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant T‑VEC + nivolumab in resectable early metastatic melanoma
2019-001911-22Phase 2Completed
- Sponsor
- Netherlands Cancer Institute
- Start
- Dec 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Oncolytic Viruses → Oncolytic Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of talimogene laherparepvec and nivolumab in cutaneous melanoma (CM) and melanoma, sponsored by Netherlands Cancer Institute. Primary endpoint: Pathologic response rate. Started Dec 2019; status: completed.
02
Drugs
talimogene laherparepvecnivolumab
03
Conditions
cutaneous melanoma (CM)melanoma
Beyond the preview
Go deeper on 2019-001911-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001911-22.